Although Hodgkin’s lymphoma (HL) is a B-cell derived cancer, the tumor cells of HL- Hodgkin and Reed-Sternberg (HRS) cells have lost the B cell phenotypes such as CD19, CD20, or CD22, and are instead characterized by bright, uniform expression of CD30, which is also shared by a small population of activated T cells (Kuppers et al., 2012). The gene discussed is CD19; the disease is neoplasm.